CRSP logo

CRISPR Therapeutics AG

CRSP
Healthcare|Biotechnology|CH
$50.07
+1.51 (+3.11%)
Tangible Book / Share
$17.04
Cash / Share
$23.49

Analyst Consensus

Buy38 analysts
Strong Buy
0
Buy
22
Hold
14
Sell
2
Strong Sell
0
Consensus Target
$64.14
Implied Upside
+28.1%
Low Target
$52.00
High Target
$80.00

Price Target Trend

Last Month
$61.00
2 targets · +22% vs price
Last Quarter
$61.00
2 targets · +22% vs price
Last Year
$65.57
14 targets · +31% vs price
All Time
$89.81
35 targets · +79% vs price

Rating Trend

Dec 25
17 buy · 10 hold · 1 sell
Jan 26
17 buy · 10 hold · 1 sell
Feb 26
18 buy · 9 hold · 1 sell
Mar 26
17 buy · 9 hold · 1 sell
Apr 26
18 buy · 9 hold · 1 sell
May 26
17 buy · 9 hold · 1 sell
Jun 26
16 buy · 10 hold · 1 sell
Jul 26
15 buy · 10 hold · 0 sell
Aug 26
14 buy · 9 hold · 0 sell
Sep 26
13 buy · 9 hold · 0 sell
Oct 26
14 buy · 10 hold · 0 sell
Nov 26
13 buy · 10 hold · 0 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Nov 4, 2026Wells FargoYanan Zhu$70.00(+40%)$49.99StreetInsider
Oct 15, 2026UBS$52.00(+4%)$50.22TheFly
Aug 6, 2026Goldman Sachs$55.00(+5%)$52.22TheFly
Jul 8, 2026H.C. WainwrightMitchell Kapoor$80.00(+32%)$60.77StreetInsider
Jun 12, 2026UBS$80.00(+59%)$50.23StreetInsider
Jun 11, 2026Morgan StanleyMaxwell Skor$60.00(+21%)$49.44StreetInsider
May 13, 2026Bernstein$56.00(+6%)$52.83TheFly
May 11, 2026Evercore ISI$76.00(+37%)$55.56TheFly
Feb 17, 2026Morgan Stanley$33.00(-37%)$52.25TheFly
Feb 14, 2026Chardan CapitalGeulah Livshits$76.00(+43%)$53.07TheFly
Feb 13, 2026Needham$82.00(+52%)$53.89TheFly
Feb 13, 2026Evercore ISI$74.00(+38%)$53.80TheFly
Nov 26, 2025Chardan Capital$74.00(+40%)$52.79TheFly
Nov 11, 2025RBC CapitalLuca Issi$50.00(-8%)$54.58StreetInsider
Oct 13, 2025Wells FargoYanan Zhu$75.00(+3%)$73.09TheFly
Feb 3, 2025H.C. WainwrightMitchell Kapoor$65.00(+63%)$40.00TheFly
Nov 6, 2024OppenheimerJay Olson$95.00(+92%)$49.51StreetInsider
Nov 5, 2024Leerink PartnersRick Bienkowski$67.00(+33%)$50.36StreetInsider
Aug 12, 2024Truist FinancialJoon Lee$100.00(+115%)$46.55TheFly
Aug 6, 2024NeedhamGil Blum$84.00(+68%)$50.11StreetInsider

Recent Rating Actions

FirmActionRatingDate
Wells FargomaintainEqual WeightNov 4, 2026
CitigroupmaintainBuyNov 4, 2026
NeedhammaintainBuyNov 3, 2026
CitizensmaintainMarket OutperformAug 31, 2026
NeedhammaintainBuyAug 31, 2026
CitizensmaintainMarket OutperformAug 25, 2026
CitigroupmaintainBuyAug 4, 2026
HC Wainwright & Co.maintainBuyJul 8, 2026
CitizensmaintainMarket OutperformJul 6, 2026
BernsteinmaintainMarket PerformMay 13, 2026
CitigroupmaintainBuyMay 6, 2026
Piper SandlermaintainOverweightMar 17, 2026
Chardan CapitalmaintainBuyFeb 17, 2026
NeedhammaintainBuyFeb 13, 2026
TD CowenmaintainHoldFeb 13, 2026
Evercore ISI GroupmaintainOutperformFeb 13, 2026
CitizensmaintainMarket OutperformJan 30, 2026
CitizensmaintainMarket OutperformDec 23, 2025
NeedhammaintainBuyDec 23, 2025
Chardan CapitalmaintainBuyNov 26, 2025
CitigroupmaintainBuyNov 12, 2025
BairdmaintainNeutralNov 11, 2025
RBC CapitalmaintainSector PerformNov 11, 2025
NeedhammaintainBuyNov 10, 2025
B of A SecuritiesmaintainBuyOct 17, 2025

Earnings History

Next report: Feb 11, 2027 · EPS est. $-1.17
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Nov 2, 2026$-1.15$-1.04$12.7M$14.8M
Aug 3, 2026$-0.94$-1.19$10.2M$7.4M
May 4, 2026$-1.28$-1.19$1.5M$6.1M
Feb 12, 2026$-1.37$-1.15$864.0K$4.7M
Nov 10, 2025$-1.17$-1.26$889.0K$9.1M
Aug 5, 2025$-2.40$-1.47$892.0K$6.1M
May 6, 2025$-1.58$-1.27$865.0K$6.0M
Feb 11, 2025$-0.44$-1.15$35.0M$8.1M

News

CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases

Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining response

Nov 8, 2026globenewswire.com
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Nov 6, 2026zacks.com
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its investigational allogeneic CRISPR/Cas9 gene-edited chimeric antigen receptor (CAR) T cell therapy targeting CD19, will be presented in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposi…

Nov 4, 2026globenewswire.com
CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates

CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.

Nov 3, 2026zacks.com
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to a loss of $1.17 per share a year ago.

Nov 2, 2026zacks.com
Casgevy Starts Paying Off for CRISPR: Rapid Earnings Reaction

CRISPR's first approved therapy is gaining traction, but the company's finances still lean on its cash reserves and an expensive pipeline.

Nov 2, 2026fool.com
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years of age and older – – FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310® for severe hypertriglyceridemia and elevated LDL-C – – Phase 1b data for CTX310 in severe hypertri…

Nov 2, 2026globenewswire.com
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nov 2, 2026zacks.com
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer

ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately.

Nov 2, 2026globenewswire.com
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.36, moving 5.34% from the previous trading session.

Oct 30, 2026zacks.com
3 Promising Genomics Stocks to Add to Your Portfolio Now

Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.

Oct 30, 2026zacks.com
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

One of CRISPR Therapeutics' leading pipeline candidates, CTX310, arguably has a larger market opportunity than Casgevy. The biotech could make significant clinical progress with this and other medicines over the next five years.

Oct 24, 2026fool.com
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.39, marking a -1.2% move from the previous day.

Oct 23, 2026zacks.com
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Oct 23, 2026zacks.com
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Oct 21, 2026zacks.com
CRISPR Therapeutics Announces Chief Financial Officer Transition

ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J.

Oct 19, 2026globenewswire.com
Where Will CRISPR Therapeutics Stock Be in 2030?

CRISPR Therapeutics has an approved product on the market that could gain significant commercial traction over the medium term. The company could also make substantial pipeline and regulatory progress.

Oct 18, 2026fool.com
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

CRISPR Therapeutics' shares have declined more than 25% over the past year. The gene-editing biotech has one approved therapy, Casgevy.

Oct 18, 2026fool.com
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.21, signifying a -4.48% move from its prior day's close.

Oct 16, 2026zacks.com
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $51.55 in the latest trading session, marking a -3.45% move from the prior day.

Oct 12, 2026zacks.com